Development, validation and application of a two-site enzyme-linked immunosorbent assay for activin-AB

in Journal of Endocrinology
Authors:
L W Evans
Search for other papers by L W Evans in
Current site
Google Scholar
PubMed
Close
,
S Muttukrishna
Search for other papers by S Muttukrishna in
Current site
Google Scholar
PubMed
Close
,
P G Knight
Search for other papers by P G Knight in
Current site
Google Scholar
PubMed
Close
, and
N P Groome
Search for other papers by N P Groome in
Current site
Google Scholar
PubMed
Close
Restricted access
Rent on DeepDyve

Sign up for journal news

Abstract

Monoclonal antibodies, specific for the βa and βb subunits of activin, were used to develop a new two-site ELISA for activin-AB. The assay had a detection limit of 0·19 ng/ml. High concentrations of activin-AB were found in bovine, ovine and porcine follicular fluids (FF), with less in human FF (1310, 1730, 688 and 7 ng/ml respectively). Recovery of spiked activin-AB standard from human, bovine and ovine FFs and from homogenized human placental extracts averaged 91%, 115%, 115% and 94% respectively. Within-plate coefficients of variation for different concentrations of activin-AB were between 1·3% and 2·67%. The between-plate coefficient of variation was 5·5%. Crossreactivity experiments showed the high specificity of the assay for activin-AB, with inhibin-A, inhibin-B, follistatin, activin-A and activin-B all cross-reacting <0·2%. Incubation with high concentrations of follistatin (500 ng/ml) prior to assay did not affect the recovery of activin-AB. Samples of bovine, porcine, ovine and human FF gave dose responses parallel to that of the standard, as did bovine granulosa cell-conditioned media. In human and porcine FF, levels of activin-A and activin-AB were similar whereas, in bovine and ovine FF, activin-A levels were approximately threefold higher than activin-AB levels. As we have reported previously for activin-A, nearly all of the endogenous activin-AB in bovine FF was detected in the eluate from gel permeation chromatography with an Mr of >700 000 indicating its association with higher molecular weight binding protein(s). By contrast, after denaturation, immunoreactive activin-AB was detected with an Mr of ∼25 000 consistent with the complete dissociation from binding proteins.

Activin-A was detected in relatively high concentrations in human FF (∼5 ng/ml), homogenized placental extracts (4·35–95·5 ng/g), sera from pregnant women (>4 ng/ml) and amniotic fluid (3–13 ng/ml), and in much lower concentrations in postmenopausal serum (500 pg/ml), normal cycle serum (100–200 pg/ml), serum from gonadotrophin-treated women (200 pg/ml) and normal adult male serum (225 pg/ml). Activin-A was also found in the culture media from explants of human amnion, chorion, maternal decidua and placenta. In marked contrast, activin-AB was undetectable (<0·19 ng/ml) in all of these samples with the exception of human FF (∼7 ng/ml).

In conclusion, we have developed a sensitive and specific ELISA to measure total (bound+free) activin-AB. Preliminary results show a more restricted distribution of this isoform compared with activin-A. The presence of high levels of both activin-A and activin-AB in FF suggests a function for both isoforms in the developing ovarian follicle.

Journal of Endocrinology (1997) 153, 221–230

 

  • Collapse
  • Expand